These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38392960)

  • 21. Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study.
    Grazzi L; Giossi R; Montisano DA; Canella M; Marcosano M; Altamura C; Vernieri F
    J Headache Pain; 2024 Feb; 25(1):14. PubMed ID: 38308209
    [TBL] [Abstract][Full Text] [Related]  

  • 22. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
    Tepper SJ
    Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-world experience with calcitonin gene-related peptide-targeted antibodies for migraine prevention: a retrospective observational cohort study at two Japanese headache centers.
    Shibata M; Fujita K; Hoshino E; Minami K; Koizumi K; Okada S; Sakai F
    BMC Neurol; 2024 Jan; 24(1):32. PubMed ID: 38238659
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monoclonal Antibodies against Calcitonin Gene-Related Peptide for Migraine Prophylaxis: A Systematic Review of Real-World Data.
    Pavelic AR; Wöber C; Riederer F; Zebenholzer K
    Cells; 2022 Dec; 12(1):. PubMed ID: 36611935
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies.
    Schwedt TJ; Lee J; Knievel K; McVige J; Wang W; Wu Z; Gillard P; Shah D; Blumenfeld AM
    J Manag Care Spec Pharm; 2023 Oct; 29(10):1119-1128. PubMed ID: 37776119
    [No Abstract]   [Full Text] [Related]  

  • 26. Migraine therapeutics differentially modulate the CGRP pathway.
    Bhakta M; Vuong T; Taura T; Wilson DS; Stratton JR; Mackenzie KD
    Cephalalgia; 2021 Apr; 41(5):499-514. PubMed ID: 33626922
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A case report of a chronic migraine patient treated with three different anti-CGRP monoclonal antibodies: which parameters better represent the efficacy?
    Uzun S; Frejvall U; Özkaya-Sahin G; Sahin G
    Front Neurol; 2023; 14():1176816. PubMed ID: 37213912
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine patients with prior preventive treatment failure: a network meta-analysis.
    Wang X; Wen D; He Q; You C; Ma L
    J Headache Pain; 2022 Sep; 23(1):105. PubMed ID: 36071388
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Change of CGRP Plasma Concentrations in Migraine after Discontinuation of CGRP-(Receptor) Monoclonal Antibodies.
    Raffaelli B; Terhart M; Fitzek MP; Lange KS; Mecklenburg J; Overeem LH; Siebert A; Storch E; Reuter U
    Pharmaceutics; 2023 Jan; 15(1):. PubMed ID: 36678920
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review.
    Blumenfeld AM; Frishberg BM; Schim JD; Iannone A; Schneider G; Yedigarova L; Manack Adams A
    Pain Ther; 2021 Dec; 10(2):809-826. PubMed ID: 33880725
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characteristics associated with response to subcutaneously administered anti-CGRP monoclonal antibody medications in a real-world community cohort of persons living with migraine: A retrospective clinical and genetic study.
    Chase BA; Semenov I; Rubin S; Meyers S; Mark A; Makhlouf T; Chirayil TT; Maraganore D; Wei J; Zheng SL; Xu J; Epshteyn A; Pham A; Frigerio R; Markopoulou K
    Headache; 2024 Jan; 64(1):68-92. PubMed ID: 38071464
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients.
    Muñoz-Vendrell A; Campoy S; Caronna E; Alpuente A; Torres-Ferrus M; Nieves Castellanos C; Olivier M; Campdelacreu J; Prat J; Camiña Muñiz J; Molina Martínez FJ; Mínguez-Olaondo A; Ruibal Salgado M; Santos Lasaosa S; Navarro Pérez MP; Morollón N; López Bravo A; Cano Sánchez LM; García-Sánchez SM; García-Ull J; Rubio-Flores L; Gonzalez-Martinez A; Quintas S; Echavarría Íñiguez A; Gil Luque S; Castro-Sánchez MV; Adell Ortega V; García Alhama J; Berrocal-Izquierdo N; Belvís R; Díaz-Insa S; Pozo-Rosich P; Huerta-Villanueva M
    J Headache Pain; 2023 Jun; 24(1):63. PubMed ID: 37268904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug-drug interaction study.
    Jakate A; Blumenfeld AM; Boinpally R; Butler M; Borbridge L; Contreras-De Lama J; McGeeney D; Periclou A; Lipton RB
    Headache; 2021 Apr; 61(4):642-652. PubMed ID: 33818780
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monoclonal Antibodies Against the Calcitonin Gene-Related Peptide and Its Receptor in Japanese Adolescents With Migraines.
    Katsuki M; Kashiwagi K; Kawamura S; Koh A
    Cureus; 2023 Jan; 15(1):e33689. PubMed ID: 36788886
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CGRP monoclonal antibodies and CGRP receptor antagonists (Gepants) in migraine prevention.
    Caronna E; Alpuente A; Torres-Ferrus M; Pozo-Rosich P
    Handb Clin Neurol; 2024; 199():107-124. PubMed ID: 38307640
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patterns of anti-CGRP mAbs use and variation of triptan consumption following treatment initiation: A descriptive drug utilization study in the Tuscany region, Italy.
    Hyeraci G; Paoletti O; Iannone LF; Gini R; De Cesaris F; Geppetti P; Roberto G
    Headache; 2023; 63(10):1391-1402. PubMed ID: 37830925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of three calcitonin gene-related peptide monoclonal antibodies for migraine: A 12-month, single-center, observational real-world study in Japan.
    Suzuki K; Suzuki S; Shiina T; Tatsumoto M; Fujita H; Haruyama Y; Hirata K
    Cephalalgia; 2023 May; 43(5):3331024231177649. PubMed ID: 37231663
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment patterns for patients initiating novel acute migraine specific medications (nAMSMs) in the context of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway.
    Zhou Z; Urman R; Gill K; Park AS; Vuvu F; Patel LB; Lu J; Wade RL; Frerichs L; Bensink ME
    J Headache Pain; 2023 Nov; 24(1):153. PubMed ID: 37946113
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis.
    Messina R; Huessler EM; Puledda F; Haghdoost F; Lebedeva ER; Diener HC
    Cephalalgia; 2023 Mar; 43(3):3331024231152169. PubMed ID: 36786548
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review.
    Yuan H; Spare NM; Silberstein SD
    Headache; 2019 Jul; 59 Suppl 2():20-32. PubMed ID: 31291020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.